Quantification of cellular viability by automated microscopy and flow cytometry

Oncotarget

Volumn 6, Issue 11, 2015, Pages 9467-9475

  Sauvat, Allan ^a,b,c   Wang, Yidan ^a,b,c,d   Segura, Florian ^a,b,c   Spaggiari, Sabrina ^a,b,c   Müller, Kevin ^a,b,c   Zhou, Heng ^a,b,c,d   Galluzzi, Lorenzo ^a,b,c,e   Kepp, Oliver ^a,b,c   Kroemer, Guido ^a,b,c,e,f  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Apoptosis; Drug discovery; High throughput screening; Necrosis

Indexed keywords

3,3' DIHEXYLOXACARBOCYANINE; CASPASE; CISPLATIN; HOE 33342; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; OXALIPLATIN; STAUROSPORINE; 3,3'-DIHEXYL-2,2'-OXACARBOCYANINE; 4',6 DIAMIDINO 2 PHENYLINDOLE; BENZIMIDAZOLE DERIVATIVE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; BISBENZIMIDE ETHOXIDE TRIHYDROCHLORIDE; CARBOCYANINE; FLUORESCENT DYE; GAP JUNCTION PROTEIN; INDOLE DERIVATIVE; NERVE PROTEIN; PANX1 PROTEIN, HUMAN; PEPTIDE CHLOROMETHYL KETONE; PLATINUM COMPLEX; TO-PRO-3;

ARTICLE; AUTOMATED MICROSCOPY; CELL DEATH; CELL FRACTIONATION; CELL FUNCTION; CELL MEMBRANE; CELL PERMEABILIZATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; EPIFLUORESCENCE MICROSCOPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICROSCOPY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NON SMALL CELL LUNG CANCER; PHENOTYPE; APOPTOSIS; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; LUNG TUMOR; METABOLISM; PATHOLOGY; PROCEDURES; ROBOTICS; STAINING; TUMOR CELL LINE; WORKFLOW;

AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; BENZIMIDAZOLES; CARBOCYANINES; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CONNEXINS; DRUG SYNERGISM; FLOW CYTOMETRY; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDOLES; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, FLUORESCENCE; NERVE TISSUE PROTEINS; ORGANOPLATINUM COMPOUNDS; ROBOTICS; STAINING AND LABELING; STAUROSPORINE; WORKFLOW;

EID: 84928753296     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3266     Document Type: Article

References (31)

1. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, et al. Classification of cell death: recommendations of the nomenclature committee on cell Death. Cell Death Differ. 2009; 16:3-11.
2. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, et al. Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death. Cell Death Differ. 2012; 19:107-120.
3. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007; 14:1237-1243.
4. Musacchio A, Helin K. Cell cycle, differentiation and disease. Curr Opin Cell Biol. 2013; 25:673-675.
5. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153:1194-1217.
6. Gitenay D, Lallet-Daher H, Bernard D. Caspase-2 regulates oncogene-induced senescence. Oncotarget. 2014; 5:5845-5847.
7. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD. Cell Death Differ. 2015; 22:58-73.
8. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov. 2011; 10:221-237.
9. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Organellespecific initiation of cell death. Nat Cell Biol. 2014; 16:728-736.
10. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX, Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med. 1995; 181:1661-1672.
11. Castedo M, Macho A, Zamzami N, Hirsch T, Marchetti P, Uriel J, Kroemer G. Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo. Eur J Immunol. 1995; 25:3277-3284.
12. Metivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I, Kroemer G. Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett. 1998; 61:157-163.
13. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 1994; 269:30761-30764.
14. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995; 376:37-43.
15. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009; 16:1093-1107.
16. Macho A, Castedo M, Marchetti P, Aguilar JJ, Decaudin D, Zamzami N, Girard PM, Uriel J, Kroemer G. Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers. Blood. 1995; 86:2481-2487.
17. Zamzami N, Maisse C, Metivier D, Kroemer G. Measurement of membrane permeability and the permeability transition of mitochondria. Methods Cell Biol. 2007; 80:327-340.
18. Qian W, Wang J, Roginskaya V, McDermott LA, Edwards RP, Stolz DB, Llambi F, Green DR, Van Houten B. Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells. Oncotarget. 2014; 5:4180-4194.
19. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER, Armstrong AJ, Penuela S, Laird DW, Salvesen GS, Isakson BE, Bayliss DA, Ravichandran KS. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature. 2010; 467:863-867.
20. Qu Y, Misaghi S, Newton K, Gilmour LL, Louie S, Cupp JE, Dubyak GR, Hackos D, Dixit VM. Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J Immunol. 2011; 186:6553-6561.
21. Bink K, Walch A, Feuchtinger A, Eisenmann H, Hutzler P, Hofler H, Werner M. TO-PRO-3 is an optimal fluorescent dye for nuclear counterstaining in dual-colour FISH on paraffin sections. Histochem Cell Biol. 2001; 115:293-299.
22. Sandilos JK, Chiu YH, Chekeni FB, Armstrong AJ, Walk SF, Ravichandran KS, Bayliss DA. Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-associated C-terminal autoinhibitory region. J Biol Chem. 2012; 287:11303-11311.
23. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Metivier D, Galluzzi L, Perfettini JL, Zitvogel L, Kroemer G. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014; 21:79-91.
24. Joo YN, Jin H, Eun SY, Park SW, Chang KC, Kim HJ. P2Y2R activation by nucleotides released from the highly metastatic breast cancer cell MDA-MB-231 contributes to pre-metastatic niche formation by mediating lysyl oxidase secretion, collagen crosslinking, and monocyte recruitment. Oncotarget. 2014; 5:9322-9334.
25. Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell death. Science. 2014; 345:1250256.
26. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31:1869-1883.
27. Liang S, Peng X, Li X, Yang P, Xie L, Li Y, Du C, Zhang G. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin. Oncotarget. 2014; 6:1020-1030.
28. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 2013; 73:2271-2280.
29. Michels J, Obrist F, Castedo M, Vitale I, Kroemer G. PARP and other prospective targets for poisoning cancer cell metabolism. Biochem Pharmacol. 2014; 92:164-171.
30. Lainey E, Wolfromm A, Marie N, Enot D, Scoazec M, Bouteloup C, Leroy C, Micol JB, De Botton S, Galluzzi L, Fenaux P, Kroemer G. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene. 2013; 32:4331-4342.
31. Montraveta A, Xargay-Torrent S, Lopez-Guerra M, Rosich L, Perez-Galan P, Salaverria I, Bea S, Kalko SG, de Frias M, Campas C, Roue G, Colomer D. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. Oncotarget. 2014; 5:726-739.